Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Celgene Poised to Boost Japan Organization as New Launch Nears
September 28, 2016
- Psoriasis Drug Lumicef to Hit Shelves on Sept. 30: Kyowa Kirin
September 28, 2016
- Sawai Files Myrbetriq Generic in US, Its 2nd Product after Livalo Copy
September 28, 2016
- Eisai Seeks Label Expansion for Fycompa to Include Monotherapy
September 28, 2016
- Novel MR Antagonist Enters Japan PIII for Hypertension: Daiichi Sankyo
September 28, 2016
- Otsuka-Lundbeck’s Alzheimer’s Med Idalopirdine Stumbles in PIII
September 27, 2016
- Rexulti OK’ed for Schizophrenia Maintenance Therapy in US
September 27, 2016
- Daiichi Sankyo Seeks RA Indication for Pralia
September 26, 2016
- Takeda, France’s Affilogic Join Hands on CNS Drugs
September 23, 2016
- Takeda Ties Up with India’s Zydus Cadila for Chikungunya Vaccine
September 23, 2016
- Maruho Gets Japan Rights to Dermira’s Hyperhidrosis Treatment
September 23, 2016
- Sumitomo Dainippon’s ADHD Drug Meets Primary Endpoint in US PII/III Study in Children
September 23, 2016
- Astellas-Vical’s CMV Vaccine Disappoints in PII for Kidney Transplant Patients
September 21, 2016
- In a Turnaround, EU Panel Backs Takeda’s Ninlaro for Conditional Approval
September 21, 2016
- Entyvio Shows Favorable Benefits in Both TNF-Naïve, TNF-Failed UC Patients
September 21, 2016
- Meiji Seika Pharma to Establish Medical Science Promotion Office in October
September 21, 2016
- Nichi-Iko to Set up Biosimilar Dept. in October to Push Remicade Follow-On
September 21, 2016
- Eisai Looks to Achieve CAGR of 55% for Fycompa with Add’l Indications
September 20, 2016
- Ono, NCC Join Hands for Discovery of Anticancer Agents, Biomarker Research
September 20, 2016
- Osaka Univ. Spinoff, Sumitomo Dainippon Ink Joint Research Pact on Antibody-Inducing Peptides
September 20, 2016
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…